BioAge Labs, Inc. (NASDAQ:BIOA) Short Interest Down 34.5% in July

Posted by Brian Himes on Aug 2nd, 2026

BioAge Labs, Inc. (NASDAQ:BIOA – Get Free Report) was the target of a significant drop in short interest during the month of July. As of July 15th, there was short interest totaling 2,451,099 shares, a drop of 34.5% from the June 30th total of 3,744,445 shares. Approximately 6.7% of the shares of the company are sold short. Based on an average trading volume of 540,360 shares, the short-interest ratio is presently 4.5 days.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Militia Capital Management LLC purchased a new position in BioAge Labs during the first quarter worth about $565,000. Stempoint Capital LP purchased a new stake in BioAge Labs in the 1st quarter valued at approximately $5,923,000. Janus Henderson Group PLC increased its position in BioAge Labs by 411.8% during the 1st quarter. Janus Henderson Group PLC now owns 2,094,270 shares of the company’s stock worth $36,597,000 after purchasing an additional 1,685,063 shares during the period. Quantinno Capital Management LP acquired a new position in BioAge Labs during the 1st quarter worth approximately $404,000. Finally, Octagon Capital Advisors LP raised its stake in shares of BioAge Labs by 9.4% during the 1st quarter. Octagon Capital Advisors LP now owns 1,748,000 shares of the company’s stock worth $30,573,000 after buying an additional 150,000 shares in the last quarter.

Analyst Ratings Changes

Several research firms recently commented on BIOA. Wall Street Zen downgraded shares of BioAge Labs from a “hold” rating to a “sell” rating in a research report on Sunday, May 17th. BTIG Research initiated coverage on shares of BioAge Labs in a research report on Wednesday, May 13th. They set a “buy” rating and a $40.00 price objective on the stock. Roth Capital restated a “buy” rating and issued a $25.00 price objective on shares of BioAge Labs in a research note on Friday. Jefferies Financial Group set a $21.00 target price on shares of BioAge Labs in a report on Friday. Finally, Needham & Company LLC decreased their target price on shares of BioAge Labs from $50.00 to $35.00 and set a “buy” rating for the company in a research note on Friday. Six research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $36.57.

View Our Latest Analysis on BIOA

BioAge Labs Price Performance

BioAge Labs stock opened at $9.04 on Friday. BioAge Labs has a 12 month low of $4.11 and a 12 month high of $25.95. The business has a 50 day simple moving average of $20.61 and a 200-day simple moving average of $19.51. The stock has a market capitalization of $401.83 million, a PE ratio of -3.77 and a beta of 0.61.

BioAge Labs (NASDAQ:BIOA – Get Free Report) last issued its quarterly earnings results on Friday, May 8th. The company reported ($0.52) earnings per share for the quarter, topping the consensus estimate of ($0.71) by $0.19. The firm had revenue of $2.77 million during the quarter. BioAge Labs had a negative return on equity of 29.40% and a negative net margin of 871.75%. As a group, equities research analysts anticipate that BioAge Labs will post -2.68 EPS for the current year.

About BioAge Labs

(Get Free Report)

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.